Ponatinib: An update on its drug targets, therapeutic potential and safety
Y Gao, Y Ding, X Tai, C Zhang, D Wang - Biochimica et Biophysica Acta …, 2023 - Elsevier
Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
R Kaddoura, WA Dabdoob, K Ahmed… - Frontiers in Medicine, 2023 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid
leukemia (CML) but their use was associated with a range of serious cardiopulmonary …
leukemia (CML) but their use was associated with a range of serious cardiopulmonary …
A decade of USFDA-approved small molecules as anti-inflammatory agents: Recent trends and Commentaries on the “industrial” perspective
Inflammation is the human body's defence process against various pathogens, toxic
substances, irradiation, and physically injured cells that have been damaged. Inflammation …
substances, irradiation, and physically injured cells that have been damaged. Inflammation …
ROCK and rolling towards predicting BCR-ABL kinase inhibitor-induced vascular toxicity
JN Upshaw, R Travers, IZ Jaffe - Cardio Oncology, 2022 - jacc.org
Chronic myeloid leukemia (CML) is the prototype for successful molecularly targeted cancer
therapy. 1 CML is caused by the Philadelphia chromosomal translocation that produces a …
therapy. 1 CML is caused by the Philadelphia chromosomal translocation that produces a …